Formulation of albumin-free erythropoietin

An erythropoietin and preparation technology, which can be applied to peptide/protein components, medical preparations containing active ingredients, and extracellular fluid diseases, etc., can solve the problems of high manufacturing cost, increased physical and chemical problems and danger
CN1832754AInactive Publication Date: 2006-09-13CJ CHEILJEDANG CORP
8 Cites 6 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
CJ CHEILJEDANG CORP
Publication Date
2006-09-13
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
Patent Text Reader

Abstract

Disclosed is a stable pharmaceutical solution preparation of erythropoietin (EPO), which includes a stabilizing agent not containing a blood-derived protein, thereby maintaining EPO activity for a prolonged period of time without the risk of viral contamination. The stable solution preparation further includes a non-ionic surfactant and a tonicity agent, thereby preventing EPO loss during storage and facilitating administration to the body.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The present invention generally relates to stable erythropoietin (hereinafter abbreviated as "EPO") solution formulations, which are free of blood-derived proteins and thus have long-term storage stability without the risk of viral contamination, and by including a stabilizer To ensure biological activity, the stabilizer can replace blood-derived components, namely albumin or refined gelatin. Background technique

[0002] EPO is a glycoprotein hormone that belongs to the class of cytokines including colony-stimulating factor (CSF), and is mainly produced in the kidney with some production in the liver. EPO plays a major role in producing mature erythrocytes by promoting the differentiation and proliferation of erythroid progenitor cells. EPO has various applications due to its effects, including the treatment of anemia associated with kidney disease, anemia requiring bone marrow transplantation, and anemia associated with rheumatoid arthritis, anemia ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More